198 related articles for article (PubMed ID: 37040760)
1. Positive selection of somatically mutated clones identifies adaptive pathways in metabolic liver disease.
Wang Z; Zhu S; Jia Y; Wang Y; Kubota N; Fujiwara N; Gordillo R; Lewis C; Zhu M; Sharma T; Li L; Zeng Q; Lin YH; Hsieh MH; Gopal P; Wang T; Hoare M; Campbell P; Hoshida Y; Zhu H
Cell; 2023 Apr; 186(9):1968-1984.e20. PubMed ID: 37040760
[TBL] [Abstract][Full Text] [Related]
2. Positive selection of somatically mutated clones identifies adaptive pathways in metabolic liver disease.
Wang Z; Zhu S; Jia Y; Wang Y; Kubota N; Fujiwara N; Gordillo R; Lewis C; Zhu M; Sharma T; Li L; Zeng Q; Lin YH; Hsieh MH; Gopal P; Wang T; Hoare M; Campbell P; Hoshida Y; Zhu H
bioRxiv; 2023 Mar; ():. PubMed ID: 36993727
[TBL] [Abstract][Full Text] [Related]
3. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Harris SE; Poolman TM; Arvaniti A; Cox RD; Gathercole LL; Tomlinson JW
Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G345-G360. PubMed ID: 32755310
[TBL] [Abstract][Full Text] [Related]
4. FGF21 protects against hepatic lipotoxicity and macrophage activation to attenuate fibrogenesis in nonalcoholic steatohepatitis.
Liu C; Schönke M; Spoorenberg B; Lambooij JM; van der Zande HJP; Zhou E; Tushuizen ME; Andreasson AC; Park A; Oldham S; Uhrbom M; Ahlstedt I; Ikeda Y; Wallenius K; Peng XR; Guigas B; Boon MR; Wang Y; Rensen PCN
Elife; 2023 Jan; 12():. PubMed ID: 36648330
[TBL] [Abstract][Full Text] [Related]
5. Comparison of Gene Expression Patterns Between Mouse Models of Nonalcoholic Fatty Liver Disease and Liver Tissues From Patients.
Teufel A; Itzel T; Erhart W; Brosch M; Wang XY; Kim YO; von Schönfels W; Herrmann A; Brückner S; Stickel F; Dufour JF; Chavakis T; Hellerbrand C; Spang R; Maass T; Becker T; Schreiber S; Schafmayer C; Schuppan D; Hampe J
Gastroenterology; 2016 Sep; 151(3):513-525.e0. PubMed ID: 27318147
[TBL] [Abstract][Full Text] [Related]
6. Hepatocyte-specific loss of LAP2α protects against diet-induced hepatic steatosis, steatohepatitis, and fibrosis in male mice.
Upadhyay KK; Choi EK; Foisner R; Omary MB; Brady GF
Am J Physiol Gastrointest Liver Physiol; 2023 Aug; 325(2):G184-G195. PubMed ID: 37366543
[TBL] [Abstract][Full Text] [Related]
7. Pathogenesis of NASH: How Metabolic Complications of Overnutrition Favour Lipotoxicity and Pro-Inflammatory Fatty Liver Disease.
Farrell GC; Haczeyni F; Chitturi S
Adv Exp Med Biol; 2018; 1061():19-44. PubMed ID: 29956204
[TBL] [Abstract][Full Text] [Related]
8. Differential TM4SF5-mediated SIRT1 modulation and metabolic signaling in nonalcoholic steatohepatitis progression.
Ryu J; Kim E; Kang MK; Song DG; Shin EA; Lee H; Jung JW; Nam SH; Kim JE; Kim HJ; Son T; Kim S; Kim HY; Lee JW
J Pathol; 2021 Jan; 253(1):55-67. PubMed ID: 32918742
[TBL] [Abstract][Full Text] [Related]
9. Growth differentiation factor 15 ameliorates nonalcoholic steatohepatitis and related metabolic disorders in mice.
Kim KH; Kim SH; Han DH; Jo YS; Lee YH; Lee MS
Sci Rep; 2018 May; 8(1):6789. PubMed ID: 29717162
[TBL] [Abstract][Full Text] [Related]
10. Disruption of hepatic small heterodimer partner induces dissociation of steatosis and inflammation in experimental nonalcoholic steatohepatitis.
Magee N; Zou A; Ghosh P; Ahamed F; Delker D; Zhang Y
J Biol Chem; 2020 Jan; 295(4):994-1008. PubMed ID: 31831621
[TBL] [Abstract][Full Text] [Related]
11. Enoyl coenzyme A hydratase 1 alleviates nonalcoholic steatohepatitis in mice by suppressing hepatic ferroptosis.
Liu B; Yi W; Mao X; Yang L; Rao C
Am J Physiol Endocrinol Metab; 2021 May; 320(5):E925-E937. PubMed ID: 33813878
[TBL] [Abstract][Full Text] [Related]
12. Loss of hepatic Mboat7 leads to liver fibrosis.
Thangapandi VR; Knittelfelder O; Brosch M; Patsenker E; Vvedenskaya O; Buch S; Hinz S; Hendricks A; Nati M; Herrmann A; Rekhade DR; Berg T; Matz-Soja M; Huse K; Klipp E; Pauling JK; Wodke JA; Miranda Ackerman J; Bonin MV; Aigner E; Datz C; von Schönfels W; Nehring S; Zeissig S; Röcken C; Dahl A; Chavakis T; Stickel F; Shevchenko A; Schafmayer C; Hampe J; Subramanian P
Gut; 2021 May; 70(5):940-950. PubMed ID: 32591434
[TBL] [Abstract][Full Text] [Related]
13. Liraglutide improves hepatic steatosis and metabolic dysfunctions in a 3-week dietary mouse model of nonalcoholic steatohepatitis.
Duparc T; Briand F; Trenteseaux C; Merian J; Combes G; Najib S; Sulpice T; Martinez LO
Am J Physiol Gastrointest Liver Physiol; 2019 Oct; 317(4):G508-G517. PubMed ID: 31460789
[TBL] [Abstract][Full Text] [Related]
14. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
[TBL] [Abstract][Full Text] [Related]
15. Hepatic Alanine Differentiates Nonalcoholic Steatohepatitis From Simple Steatosis in Humans and Mice: A Proton MR Spectroscopy Study With Long Echo Time.
Kim TH; Jun HY; Kim KJ; Lee YH; Lee MS; Choi KH; Yun KJ; Jeong YY; Jun CH; Cho EY; Yoon KH
J Magn Reson Imaging; 2017 Nov; 46(5):1298-1310. PubMed ID: 28225569
[TBL] [Abstract][Full Text] [Related]
16. Pleiotropic actions of IP6K1 mediate hepatic metabolic dysfunction to promote nonalcoholic fatty liver disease and steatohepatitis.
Mukherjee S; Chakraborty M; Ulmasov B; McCommis K; Zhang J; Carpenter D; Msengi EN; Haubner J; Guo C; Pike DP; Ghoshal S; Ford DA; Neuschwander-Tetri BA; Chakraborty A
Mol Metab; 2021 Dec; 54():101364. PubMed ID: 34757046
[TBL] [Abstract][Full Text] [Related]
17. Fibrinogen-like protein 2 aggravates nonalcoholic steatohepatitis via interaction with TLR4, eliciting inflammation in macrophages and inducing hepatic lipid metabolism disorder.
Hu J; Wang H; Li X; Liu Y; Mi Y; Kong H; Xi D; Yan W; Luo X; Ning Q; Wang X
Theranostics; 2020; 10(21):9702-9720. PubMed ID: 32863955
[No Abstract] [Full Text] [Related]
18. The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent.
Mancina RM; Dongiovanni P; Petta S; Pingitore P; Meroni M; Rametta R; Borén J; Montalcini T; Pujia A; Wiklund O; Hindy G; Spagnuolo R; Motta BM; Pipitone RM; Craxì A; Fargion S; Nobili V; Käkelä P; Kärjä V; Männistö V; Pihlajamäki J; Reilly DF; Castro-Perez J; Kozlitina J; Valenti L; Romeo S
Gastroenterology; 2016 May; 150(5):1219-1230.e6. PubMed ID: 26850495
[TBL] [Abstract][Full Text] [Related]
19. Discovering a critical transition state from nonalcoholic hepatosteatosis to nonalcoholic steatohepatitis by lipidomics and dynamical network biomarkers.
Sa R; Zhang W; Ge J; Wei X; Zhou Y; Landzberg DR; Wang Z; Han X; Chen L; Yin H
J Mol Cell Biol; 2016 Jun; 8(3):195-206. PubMed ID: 26993042
[TBL] [Abstract][Full Text] [Related]
20. Nonalcoholic Steatohepatitis.
Suzuki A; Diehl AM
Annu Rev Med; 2017 Jan; 68():85-98. PubMed ID: 27732787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
